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Introduction
Tumor suppressor p53 is a key inhibitor for tumor development in human and animals. Breast cancer is the most frequent tumor observed in women carrying p53 germline mutations. In mice, mammary tumors are common among BALB/c-Trp53+1-females but rare among C57BL/6-Trp53+1-females (1, 2) . The inherited difference in cancer susceptibility between the two strains provides a model system to study genetic modifiers (both high-and low-penetrance alleles) that contribute to breast cancer susceptibility. In the previous report, we have mapped a 10Mb region on mouse chromosome 7 that contains a recessive-acting gene that could be responsible for the mammary tumor susceptibility in BALB/c mice. Gene microarray analysis further revealed that Deleted in Malignant Brain Tumors 1 (DMBTi) is a leading candidate. Loss or reduction in DMBTI expression has been broadly reported in various of epithelial cancers, including breast cancer (3) (4) (5) (6) . In this report, we provided evidence that low DMBTI expression is associated with tumor susceptibility in mice and human. INTRODUCTION
Loss of heterozygosity (LOH) occurs commonly in cancers causing
Loss of heterozygosity (LOll) plays an important role in carcinodisruption of tumor suppressor genes and promoting tumor progression, genesis in both sporadic and familial cancers. LOH is a means by BALB/c-Trp53+1-mice are a model of Li-Fraumeni syndrome, exhibiting which mutations, germline or sporadic, in tumor suppressor genes can a high frequency of mammary tumors and other tumor types seen in become homozygous leading to tumor predisposition in the affected patients. However, the frequency of mnammary tumors and LOH differs cells (I, 2) . Mutations in the p53 tumor suppressor gene are cornamong strains of Trp53+1-mice, with mammary tumors occurring only on monly observed in human cancers and occur together with LOI I at the a BALB/c genetic background and showing a high frequency of LOH, TP53 locus (3, 4). Although the p53 tumor suppressor gene (TP53 in whereas Trp)53-mice onl a 129/Sv or (C57BL/6 X 129/Sv) mixed backhumans or Ttp53 in mice) is critical for inhibiting tumor development ground have a very low frequency of mammary tumors and show LOHl froru ind ony5 ftuorsW have performe studies onwfrequencyofm tumors ain many tissues, the breast epithelium appears particularly dependent for Trp53 in only -50% of tumors. We have performed studies on tumors from Tip53+/-mice of several genetic backgrounds to examine the mechon proper p53 function. This is evident from the high frequency of anism of LOHl in BALB/c-Tip53'/-mammary tumors. By Southern mutations in TP53 in sporadic human breast cancers (5) and the high blotting, 96% (24 of 25) of BAIB/e-Trp53+/-mammary tumors displayed frequency of breast cancer in Li-Fraumeni syndrome patients (LFS), LOH for Trp53. Karyotype analysis indicated that cells lacking one copy of whom approximately half carry mutations in one allele of TP53 (6) . of chromosome II were present in all five mammary tumors analyzed but Even in the context of mutations in the breast cancer susceptibility were not always the dominant population. Comparative genomic hybridgenes, BRCAI and BRCA2, high rates of p53 mutation are found (7, ization analysis of these five tumors indicated either loss or retention of 8) and inactivation of p53 is frequent in the development of mammary the entire chromosome II. Thus chromosome loss or deletions within tumors in Brcal or Brca2 conditional mutant mice (9, 10) . Thus p53 chromosome 11 do not account for the LOH observed by Southern mutation and LOH appear to play particularly prominent roles in the blotting. Simple sequence length polymorphism analysis of (C57B L/ development of breast cancer. 6 x BALB/c) FI-Trp53+/ mammary tumors showed that LOH occurred Mice heterozygous for the D1p53 null allele develop a spectrum of over multiple loci and that a combination of maternal and paternal alleles tumors similar to LFS patients (11, 12). However, only when the were retained, indicating that mitotic recombination is the most likely mechnis of[Oi.
Nnnimmay tmor ofB~iB/cmic alo sowe
Trlp53 null allele was backerossed onto the BALB/c genetic backmechanism of LOH. Nonmammary tumors of BAIB/e mice also showed g o n a h i h fe u n y o a m r un r e ni F a high frequency of LOH (22 of 26,85%) indicating it was not a mammary ground was the high frequency of mammary tumors seen in LFS tumor specific phenomenon but rather a feature of the BALB/c strain. In patients recapitulated (13) . Therefore BALB/c-Trp53+-mice serve (C57BL/6 x BALB/c) Fl-Trp53+/-mice LOH was observed in 93% (13 of as a unique model for breast cancer in LFS. The BALB/c suscepti-14) of tumors, indicating that the high frequency of LOH was a dominant bility to Tip53+/ mammary tumors has both dominant and recessive genetic trait. Thus the high frequency of LOH for Trp53 in BALB/cgenetic components, as determined by breeding with the C57BL/6 Trp53+/-mammary tumors occurs via mitotic recombination and is a strain (14) . Female BALB/c-Trp53 --mice developed mammary dominant genetic trait that associates with the occurrence of mammary tumors at a frequency of 55% and a latency of 8-14 months, with the tumors in (C57BL/6 x BALB/c) F1-Trp53+-mice. These results further majority being adenocarcinomas that exhibit karyotypic instability implicate double-strand DNA break repair machinery as important conand are often aneuploid (13) . Mammary tumors arising in BALB/ctributors to mammary tumorigenesis.
Tip53+/-mice exhibited a high frequency of loss of the wild-type nary and Animal Sciences tinder projects MAS00821 and NC-1010. A. C. Blackburn was Various mechanisms can result in LOH that may or may not lead to supported by Department of Defense Breast Cancer Program Award DAMD17-01-1-changes in gene copy number, thus affecting our ability to detect 0315, administered by United States Army Medical Research Acquisition Activity, and ,subsequently by Fellowship 179842 awarded by the National Health and Medical Re-LOH. Loss of an entire chromosome by iissegregation will lead to search Counci I of Austral ia. LOH along the entire chromosome length, and unless accompanied by
The costs ofppublication of this article were defriayed in pait by the payment of page rdlication, this loss will result in only one copy of that chromocharges. This article must therefore be hereby tnarked advertiuement in accordance with re tip 18 U.S.C. Section 1734 solely to indicate this fact. some being present. Recombination between homologous chromoNote: A. C. Blackburn is currently in John Curtin School of Medical Research, somes rather than sister chromatids during mitosis (mitotic recombiAustralian National University, Canberra, Australia. R. Nacem is currently in Baylor
College of Medlicine, Houston, Texas. S. P. Naber is currently in Tufts-New England nation, MR) will result in LOH occurring over the distance between Medical Center, Boston. Massachusetts.
the recombination break points, with multiple rounds of this over although maintaining two copies of each gene. Deletion events, per-Biosystems), heated at 95°C for 5 rain, and cooled on ice. Then 1.5 pI of the haps occurring as a result of nonhomologous end joining (NIHIEJ) of mixture was loaded in a 5% denaturing polyacrylamide gel and electrophoredouble-strand DNA breaks, will result in LOll and a reduction in gene sed for 2.5 h on an ABI PRISM 377 DNA Analyzer to determine tile sizes of dosage for loci within the deleted region.
the PCR products. Mice. BALB/c-Trp53'-mice were generated previously (17) by backprecipitated with ethanol, rinsed in 70% ethanol and air-dried, The same crossing (C57BL/6 X 129/Sv) Trp5y3--mice onto the BALB/cMed strain for procedure was repeated with the Cy5-labeled tail and Cy3-labeled tumor II generations. Fl intercross mice were Ttp53 /-offspring of inbred C57BL/ DNAs. The pellets were dissolved in 10 li 1 of distilled water and mixed with 6J-Trp53/•' female and BALB/cMed-Trp53-/-male mice. N2 backcross 30 jig of hybridization solution (50% formamide, 10% dextran sulfate in mice were the offspring of' (C57BL/6J X BALB/cMed) Fl-Trp53"'/ fe-2 X SSC). The labeled DNAs were denatured at 72°C for 10 ruin fbllowed by males X BALI3/cMed-Trp53-males. Ninety-seven virgin female BALB/cincubation at 37°C for 30 min to block repetitive sequences. Oppositely Trp53 "-, 19 virgin female (C57BL.!6 X BALB/c) FI-T1T53 '-study mice, labeled DNA mixes (Cy3-labeled test and Cy5-labeled reference DNA, Cy3-and 224 virgin female [(C57BL/6 X BALB/c) X BALB/c] N2-Trp53' study labeled reference and Cy5-labeled test DNA) were added onto duplicate mice were monitored weekly for tumor development or morbidity and were microarray slides. Hybridization as per the Spectral Genomics protocol was palpated for mammary tumors. The survival from and the occurrence of overnight at 371C. Slides were washed at room temperature 2 X SSC for 3-5 mammary and other tumors in these mouse populations has been described min, then washed at 50'C for 20 min with shaking itt 50% formamnidei previously (14) .
2 X SSC. The wash step was repeated with prewarmed (50'C) 0.l%NP40/ Tumors from male and female Trp53+'-mice of mixed [C57BL/6 X 129. ' 2 x SSC for 20 min and with 0.2 X SSC for 10 min at 5"C. The microarrays Sv] background analyzed for LOlH are those that have been described previwere briefly rinsed with distilled water at room temperature for 3-5 s and ously (15, 18) . Kaplan-Meier plo t s of survival (n = 96 females, n = 113 male) wre nalzedby he lg-rnk est(MatelCox)forsigifiantdiferimmediately centrifuged for 3 mmi at 500 X g for drying. ltybridized taicroarmiles) were analyzed by t.e log-rank test (Mantel-Cox) for significant differ-ray slides were scanned with GenePix 4000B scanner (Axon Ins. Inc., Union Isolation ot'Genomic DNA. Genomic DNA for Southem blotting, PCR, and City, CA), and the data obtained were analyzed using the Spectralware 1.0 Isoltio ofGenmic NA.GenmicDNA or outernblotin-PCRand software (Spectral Genomics). SpectralWare was u~sed to normalize the Cy5: comparative gentomic hybridization were extracted from tumors and normal tail tissues of Tip53. mice. The tissues were snap frozen in liquid nitrogen at the Cy3 intensity ratios for each slide such that the summed Cy5 signal equals the time of necropsy, later minced and digested ovemnight with 100 g/n-ml proteinase summed Cy3 signal. The normalized Cy5:Cy3 intensity ratios were computed K in 100 tmut Tris, 5 mm EDTA, 0.2% SDS, and 200 mm NaCI. Genoriic DNA for each of the two slides and plotted together for each chromosome. Gains in was extracted with phenol/chlorofomr 'isoamnyl alcohol (25:24:1) .
DNA copy number at a particular locus are observed as the simultaneous Trp53 Genotyping and LOl. The Trp53-S-males used for generating the deviation of the ratio plots from a modal value of 1, with the blue ratio plot
Trp53+-mice were genotyped by multiplex PCR as described previously (1I, showing a positive deviation (upward) whereas the red ratio plot shows a 17). LOII in tumors at the Trp53 locus was determined by Southern blotting as negative deviation at the same locus (downward). Conversely, DNA copy described previously (13) . Briefly, genomic DNA was digested with Stul and number losses show the opposite pattern. EcoRI, blotted and hybridized with a probe spanning exon 7 to exon 9 of the Karyotypic Analysis of Mammary Tumors. Primary nmaimmaryepithelial Tr)53 gene. The intensity of the wild-type and null bands was quantitated cell cultures were prepared from mammary tumors arising in I3ALB/cusing a phosphorimager (Cyclone; Packard Bioscience, Boston MA) and the Trp53+'-mice. Tumor tissue was minced finely with razor blades and diOptiQuant software package. Time ratio of wild-type:null band hybridization gested in mamnary epithelial cell media [consisting of DMEM/F12 (Sigma) values was calculated. Loss of the wild-type allele was defined as wild-type: plus 25 mm HEPES, 1.2g/L NaHCO, 10 ttg/ml insulin, 5 ng/ml EGF] supplenull <0.5. Statistical significance for the frequency of LOtl was determined by mented with 2% adult bovine serum and 0.4% collagenase type III (Life Fisher's exact test.
Technologies, Inc.) at 37°C for 3-4 h with gentle agitation. The digested cell Genotyping at SSLP Loci. The normal and tumor-derived DNA samples suspension was then washed several times in PBS, and the finer clumps of cells from F I-and N2-study mice were genotyped using fluorescently labeled PCR were plated in flasks with nammary epitielial cell plus 2% adult boviti serum primers that amplify five SSLP markers on chromosome II (Applied Biosysand grown 1-2 nights until a monolayer was formed. Cells were then grown in temns, Foster City, CA antd Research Getictics, Huntsville. AL). Reactiot an d rw -ihsuii ooae a otmd el eete rwii volmes Fofe 7ity, CA wereud Resntaitii eng ti. ,Hunfsaviille, D AL). atR20 c mammary epithelial cell media plus 5% fetal bovine serum overnight followed olm of locus specific primer mix at 4 MM cotncentration each, 4. ×< 129/ more stromal tissue, which may account for the presence of more Sv) background and examined both males and females, whereas this wild-type allele in the sample, with one being a papillary ductal study used all BALB/c female mice; therefore, both strain and gender hyperplasia and the other being a solid adenocarcinoma but with a could be contributing to the difference in LOH frequency. To detersignificant fibrous stromal component. Interestingly, the remaining mine whether gender affects the frequency of LOI l, tumors analyzed tumor (V 15) showed complete loss of the null allele, indicating that previously for LOH (15) were segregated according to gender, and the genetic changes had occurred but not with the usual outcome. Thus frequency of LOH was calculated. Tumors from females showed a loss of the wild-type allele was detected in 24 of 25 (96%) mammary significantly higher frequency of LOH compared with males, with tumors by Southern blotting. 59% of tumors from females showing LOll compared with only 21% This high frequency of LOH contrasts with previous reports of of male tumors (P = 0.006). The frequency of LOH in the female 50-70% of spontaneous tumors from Trtp53' -mice showing LOll (C57BL/6 × 129/Sv) tumors was still significantly lower than in for Trp53 (11, 15, 18, 19) . To determine whether this high frequency female BALB/c tumors (P = 0.046; Table 1 ). Thus, both a strain of LOUt was particular to mammary tumors, other tumor types arising effect and a gender effect contribute to the high frequency of LOI in in BALB/c-Tip53"/-mice were examined for LOH. Lymphomas, female BALB/c-TIp53+-tumors. sarcomas, and adrenal gland tumors collected from female virgin and Loss of the wild-type allele of Trp53 has been suggested to accelbreeder BALB/c-Trp53+/-mice showed a high frequency of LO-I erate tumor formation (15). To determine whether the rate of tumor-(22 of 26 tumors) that was similar to the mammary tumors (P = 0.35; igenesis correlated with the frequency of LOH, the survival of male Table 1 ). Thus the high frequency of LOH is not restricted to marn-and female Tip53+-mice of mixed [C57BL/6 × 129/Sv] backmary tumors.
RESULTS
ground was analyzed (Fig. 2 ). Female mice were found to have a There are two differences between the mice used in this study and significantly shorter survival time than their male counterparts, with the previous studies reporting lower frequencies of LOH in tumors, median survival times of 70 and 80 weeks respectively (P < 0.0001).
null-* wt__* ..... The majority of tumors show almost complete loss ofsignal from the wild-type allele. The ratio wild-type:null band for VI5 was >0.5, indicating retention of the wild-type allele. A p53 pseudogene also weakly hybridizes with the probe (pseudo). WIt, wild-type.
RATES IN 7rp55.3`-TUMORS
however, consistent with the karyotype of the dominant cell popula-1 ,tion within the metaphase samples. Thus, MTuV02, containing 50% diploid cells shows no loss on chromosome I by CGII, whereas .. 8
MTuV14 containing 65% aneuploid cells shows loss of the entire n chromosome I I by CGII (Table 2 the hypodiploid population appears to be the progenitor of the polyploid population of cells. In other tumors, the polyploid cells also show evidence of further genomic instability with double minutes This difference in survival was not accounted for by gender-specific present that are characteristic of amplified segments of the genome. tumors because there were essentially no mammary, ovarian, or
In contrast to both the karyotype and CGII results, Southern blotuterine cancers in the TDp53 ' females included in this analysis. ting indicated the unambiguous loss of one allele of 77)t53 in 4 of 5 Wild-type females (lid not show statistically significant differences in of these tumors, including MTuV14 ( Table 2 , Fig. 1 ). This was survival compared with wild-type males, albeit the numbers of wild-especially the case in V02, where the population of hypodiploid cells type mice analyzed were low (data not shown).
was only 25% of the total, loss along chromosome II was not To detenmine whether the genetic factors leading to LOll in BALB/ detectable by CGII (Fig. 3) , and yet >90% loss of one Ttp53 allele c-Ttp53 '/-mice were dominant or recessive, tumors arising in the was detected by Southern blot hybridization (Table 2 ). This is indic-(C57BL/6 X BALB/c) FI--Tr)53' . mice were analyzed for LOII. ative of LOI I occurring by a mechanism other than chromosomal loss Wilh the exception of the benign sclerosing adenosis of the mammary and before tile development of aneuploidy. gland, all tumors examined showed loss of the wild-type allele (Table  LOH at SSLP Markers. The FI and N2 mice are heterozygous for I) giving a frequency of 93%. This was not different from the C57BL/6 and BALB/c polymorphic markers throughout the genome, firequency for all BALB/c-Trp53'/-tumors (90%) and was signifi-allowing more extensive analysis of LOll in tumors arising in these cantly different from the (C57BL/6 X 129/Sv) female frequency mice. Because the number of Fl mammary tumors available was (59%, P = 0.035) indicating that it was a dominant genetic trait.
small, informative N2 mammary tumors were analyzed in addition to To determine whether the frequency of retention of the wild-type all of the Ft tumors. SSLP markers spanning 1.1-37 cM of chromoallele increased with age, mammary tumors from [(C57BL/ some I Iwere used to analyze 21 tumors from Fl-and N2-Trp53+/-6 X BALB/c) x BALB/c] N2-Trp53+ /-mice (acquired previously in mice. The genotyping of the normal tail DNA from F l mice was used an experiment genetically mapping recessive factors contributing to to define the haplotype of the paternal chromosome bearing the Trp53 mammary tumor susceptibility; Ref. 14), were examined. Because of null allele (Fig. 4A ). The paternal chromosome I I carried BALB/c the size of this study population and the mixed genetic background of alleles for all markers except Dl IMIT4 (located at 37 cM). This was mice, considerable numbers of mammary tumors from older mice expected because the Trp53 null allele (located at 39 cM) was genwere able to be collected. LOll was analyzed in the earliest 12 erated in embryonic stein cells from 129/Sv mice (11). The markers (21.4-46.9 , mean latency 36.7 weeks) and the latest 14 (66.9-77.6 . were all informative in the F I mice, and therefore were used to deduce mean latency 69.4 weeks) occurring mammary tumors. Interestingly, the haplotypes of tumors arising in these mice. Tumors froom FI mice two of the early-onset tumors (21.4 and 40 weeks) retained the wild-type allele, whereas all other mammary tumors, old and young, were either hypodiploid or near-tetraploid. Loss of one copy of CH. comparative genomic hybridization; chr, chronosomc; LOU, loss of itterozychromosome 11 was observed in the hypodiploid population of each gosity.
tumor (Fig. 3) . In contrast, loss of one entire copy of chromosome I I • [,present at many of the SSLP loci examined in the tumors (Fig. 4 mammary tumors than in other tumor types. The initial report on mammary tumors in BALB/c-Tip53+-mice (Table 2) . A translocation of chromosome 10 to chromosome I (ti:10) has occurred (box) found a high frequency (seven of seven) of LOlt for the wild-type providing a "marker chromosome" in the kayotype. B, the polyploid cell is near Trp53 allele (13) . The current report confirms and expands that tetraploid. The presence of tile t1:10 marker chromosome suggests that the polyploid cells are derived froom the hypodiploid population, C, CGI-ratio plots from nlamma'y tumors finding with the analysis of 57 more spontaneous mammary tumors showing loss (Vt4) or no loss (V02) of chromosome II.
from both BALB/c and mixed (C57BL/6 X BALB/c) genetic backgrounds using Southern blotting, karyotyping, CGH, and SSLP analysis to examine the mechanism of LOll in these mammary tumors. included five mammary adenocarcinomas, one benign sclerosing ad-Southern blotting demonstrated that a high degree of LOH for T7p53 enosis of the mammary gland and seven tumors from other tissues. An was found in 93% of mammary tumors ( Fig. 1; Table 1 ). Karyotype initial screen of normal tail DNA from 13 N2 mice bearing mammary analysis indicated that cells lacking one copy of chromosome 11 were tumors was performed and the eight mice bearing the most inforna-present in all five mammary tumors analyzed but were not always the tive polymorphisms were selected for further analysis. LOll and dominant population ( Table 2 ), suggesting that loss of chromosome haplotypes of N2 tumor alleles were determined by comparison with II was not an early event in tuinorigenesis and could not account for normal tail DNA from the same mouse, the high degree of LOl-observed by Southern blotting. CGIHI analysis Examination of five SSLP markers allowed tile tumors to be clas-indicated either loss or retention of the entire chromosome 11, thus sified into four groups, as shown in Fig. 4 , B--E: (B) retention of eliminating deletions within chromosome II as a mechanism of LOl0 heterozygosity (no LOH) at all markers; (C) LOll at all markers with (Fig. 3) . SSLP analysis showed that LOH occurred over multiple loci, the paternal alleles being retained; (D) LOlH at all markers with a and that a combination of maternal and paternal alleles were retained, mixture of maternal and paternal alleles being retained; and (E) LOH indicating that MR is the most likely mechanism of LOH (Fig. 4) . at some markers and a mixture of maternal and paternal alleles being Thus we propose a model for the genetic progression of spontaneous retained. These classifications are based on the markers analyzed that Trp7a53+ mammary adenocarcinomas whereby loss of the wild-type are assumed to be indicative of the rest of the chromosome. Two allele of Trp53 occurs as a result of MR, which may be followed by tumors were found to have retained heterozygosity at all markers ( Fig. missegregation and Mitotic recombination is thought to be responsible for the ma-such as transcriptional transactivation and cell cycle control (26-jority of LOI that occurs spontaneously in normal somatic cells. 28) and Trp53+/-mouse fibroblasts had 3-fold the frequency of This is indicated by studies on LO1H for the [ILA locus in cultured homologous recombination compared with wild-type cells, indihuman lymphocytes (20) , on the pink-eyed unstable locus in mice eating a moderate haploinsufficiency for suppression of homolo- (21) and on the Aprt locus in human lymphocytes and mouse gous recombination (28). However, repression of recombination is fibroblasts (22, 23) . The gender bias observed in LO frequency in much more modest, if detectable, in the context of endogenous loci Trp53 " tumors (59% in females versus 21% in males, Table 1 ) and interchromosomal recombination events (21, 29) . Even withis consistent with LO occurring by MR as it has been shown in out elevated rates of recombination, the background rate of recomhuman lymphocytes that MR rates are 2.5-fold higher in females bination in Trp53+/--tissues may be amplified because of haplocompared with males (20) . Numerous studies have reported that insufficiency for p53 transcriptional activation, cell cycle arrest wild-type p53 suppresses homologous recombination, measured as and apoptosis (30) (31) (32) , allowing the accumulation of more recomintrachromosomal recombination in integrated plasmid substrates bination events over time compared with wild-type cells. Mitotic with short tracts of homology (24, 25) . In this context, repression recombination frequencies are inhibited by a high degree of chroof recombination may occur independently of other p53 functions mosomal divergence as exists between some mouse strains (33);
observed in the BALB!c strain. Once the wild-type allele of Tip53 has been lost, general genomic
The finding of a comparable frequency of LOIl in the Fl-Trp53+ -instability and aneuploidy will occur as is characteristic of p53-tumors indicates that the elevated frequency of LO1 in the BALB/c deficient tumors (34). Chromosomal missegregation without redupli-strain is a dominant genetic trait. We have reported previously that the cation could leave the cells with only one copy of chromosome 11 and occurrence of BALB/c-Tip53+ -mammary tumors also has a domalead to deficiency in other tumor suppressor genes such as Brcal inant genetic component, with 32% of female (C57BL/6 X BALB/c) which lies at 60 cM on mouse chromosome 11. However, the incon-Fl-Trp53+-developing mammary tumors compared with <1% in sistent demonstration of loss of chromosome II by CGII in the published reports for C57BL/6 mice (14) . Thus, the high frequency of manmmary tumors argues against the existence of a strong selective tumor LOH for Tiyp53 associates with the occurrence of mammary pressure for cells possessing only one copy of chromosome 11. This tumors. Although LOH for Trp53 occurred equally among tumor is further supported by Southern blotting analysis, which indicated no types, the number of recombination events that occurred in the tumors significant loss of allcles at the Brcal locus in BALB!c-Tjp53 /-was not equal. SSLP analysis of paternal and maternal alleles retained mammary tumors (13) . These results support the proposed model in within the tumors indicated that recombination events may be more which LOI I for Trp53 by MR occurs as an earlier and more significant common in mammary tumors than in other tumor types. This would event in mammary tumnongenesis than loss of chromosome 11 in this be consistent with the higher frequency of LOHl for p53 in LFS breast mouse model, cancer compared with other tumor types. Tumor-specific LOH may be A comparison of the LOll results from this study with what is the result of several different mechanisms, discussed in Monteiro (41), known in LFS patients is favorable for this mouse model being including tissue-specific differences in recombination rates. Studies relevant to the humnan setting. In a detailed study of LOll for TP53 in on MR in mouse fibroblasts and T-lymphocytes support the notion LFS tumors, Varley et al. (16) found LOll occurring in 44% of that MR is regulated in a tissue-specific manner (33, 42) . If MR tumors. Examination of allclic imbalance along chromosome 17 by determines the rate of LOH in spontaneous tumors of this model, and microsatellite analysis produced similar findings to the mouse tumors mammary tumors undergo higher rates of MR than other tissues, then of this study. Although some tumors showed LOI I or allelic imbal-a further increase because of strain differences in the MR rate may ance at all loci, consistent with loss of an entire chromosome, the greatly amplify the LOll rate in the mammary gland over other majority of tumors showed LOH for only part of the chromosome. tissues, thereby specifically accelerating mammary tumor developVarley et al. note that the relative frequency of this pattern of LOlL is ment. Thus, we hypothesize that elevated MR rates may contribute to higher in their LFS tumors than that reported for other tumor types, the high susceptibility of BALB/c-Trp53'/-mice to mammary tusuch as retinoblastoma. This may be because of haploinsufficiency for mors compared with other strains. suppression of MR by p53 in the heterozygous LFS patients. InterIf reduced DNA-PK activity is contributing to a higher frequency of estingly, when LOH frequency in LFS breast cancers alone was LOH, this may have a particularly strong impact on the mammary considered, 11 of 14 or 79% (seven of eight in the Varley el al. study gland because DNA-PK activity is already low in normal mouse (39) and four of six in other published studies: Ref. 16 ) of tumors show and human (43) mammary glands compared with other tissues. Prkdc LOHl. Thus, LOH for TP53 occurs at a much higher frequency in has been suggested as the gene responsible for BALB/c susceptibility breast cancer than in other tumor types. The effect of gender on LOH to radiation-induced mammary tumors (39) . We have demonstrated in LFS cannot be assessed from these reports because the published clearly that the Prkdc allele is not a major recessive locus contributing genders of these LFS patients is incomplete. However, female carriers to spontaneous mammary tumor susceptibility in BALB/c-PTp53+H-of p53 mutations have been shown to have a consistently higher mice (14) , but its dominant actions have not been characterized. In cancer risk compared with male carriers (35), even after the exclusion humans, a study has recently been published examining breast cancer of cases of breast, ovarian, and prostate cancer. This aspect of LFS is risk and polymorphisms in five NVIEJ genes, Ku70, Ku80, DNA-PKcs, recapitulated in the Ttp53+1-mouse model (Fig. 2) and correlates Ligase IV, and XRCC4 (44). In a multigenic analysis, increased risk of with the higher frequency of LOH in female mice ( Table 1) . Hwang developing breast cancer was found in women harboring a greater el al. (35) do not speculate on the mechanism for the sex difference in number of putative high-risk alleles of NHEJ genes, which was cancer risk, but it is tempting to suggest that a higher frequency of stronger and more significant in women thought to have a greater LOll of TP53 occurring in female patients contributes to earlier onset exposure to estrogen (i.e., no full-term pregnancies; Ref. 44) . This is cancers than in males, although the influence of estrogen as a tumor consistent with our hypothesis for BALB/c mice, which stated that promotor generally cannot be excluded, elevated MR and decreased DNA-PK activity contribute to mammary Analysis of nonmammary tumors arising in BALB/c-Trp53`• mice tumor susceptibility. The shortcoming of this population study is the demonstrated that LOH occurred at a similar high frequency to mammary lack of functional information for the single nucleotide polymorphism tumors (Table 1) . Thus, rather than being restricted to malnlnary tumors, alleles examined. It would be valuable to test this hypothesis with the high fircquency of LOH is characteristic of the BALB/c strain. One polymorphisms of known functional consequence, either in mouse potential contributor to this trait is the hypomorphic BALB/c allele of models or in population studies, to confirm the mechanism responsiPrkdc (36), the gene encoding the catalytic subunit of DNA-dependent ble for the risk association identified in Fu etal. (44) and in our study. protein kinase (DNA-PK). DNA-PK has been reported to suppress inOther genes and pathways are potentially involved in the dominant duced and spontaneous homologous recombination (37) . DNA-PK is also mammary tumor phenotype observed in these mice. However, the an essential component of the NHEJ pathway for DNA double-strand finding that recombination may be responsible for loss of the wildbreak repair (38) . A deficiency in NHEJ may increase the proportion of type allele of Trp53 in spontaneous mammary tumors in Trp53+1-double-strand break repaired by alternate pathways such as recombina-mice implicates the recombination machinery in the tumorigenic tion. BALB/c mice have been found to have two missense mutations in process of the BALB/c mouse mammary gland. Both BRCA 1 and Prkdc, resulting in decreased protein levels, DNA-PK activity and BRCA2 have been shown to be involved in repair of double-strand double-strand break joining activity compared with most other mouse break particularly via recombination (38, 45) . Additional studies are strains (36, 39, 40) . This deficiency in DNA-PK function may promote required to determine the underlying reason for the high frequency of 5146 t011 RATES IN bi,53 TUOR 1_0l1 and recombination observed in these tumnors and the relationship 22. Gupta PK, Sahota A, Boyad~iirv SA, et al. Hligh frequency in vivo loss of heter'ozyto the breast cancer susceptibility of the BALB/c strain. 
Genetic mapping in mice identifies DMBT1 as a
Heritable breast cancer is a complex disease with multiple genes contributing to overall risk. A genetic screen using intercross progeny from strains of Trp53+/-mice that differ in incidence of mammary tumors identified a recessive modifier of mammary tumor susceptibility on mouse chromosome 7 (designated SuprMaml). Relative to heterozygotes, homozygosity for BALB/c alleles of SuprMam I significantly decreased latency of mam mary tumors.
Dmbtl (deleted in malignant brain tumor 1) was identified as a candidate because it was the only gene within the SuprMaml interval that showed reduced expression in mammary glands of the susceptible BALB/c mice and was a putative tum or suppressor. DMBT1 protein expression was also significantly reduced in breast epithelium among women with breast cancer compared with cancer-free controls.
SIGNIFICANCE
Low-penetrance breast cancer susceptibility alleles appear to play a significant role in modifying breast cancer risk.
However, analysis of human cohorts has very limited statistical power to identify modifier genes with lowpenetrance. These experiments demonstrate the use of Trp53'-mice as a sensitized background to screen for novel low-penetrance modifiers of cancer. The results identify a new class of breast cancer susceptibility alleles that are inherited as recessive traits and support a role for DMBT1 in suppression of mam mary tumors in both mice and women. As low levels of DMBTI expression are associated with increased risk of breast cancer, it provides a novel tool with which to assess risk of recurrence among breast cancer patients as well as providing a target for therapeutics.
INTRODUCTION
Approximately 27% of breast cancer risk has been attributed to genetic factors (Lichtenstein et al., 2000) .
Highly penetrant, dominant alleles of genes such as BRCA1, BRCA2 and TP53 confer a high risk of developing breast cancer; however, mutant alleles such as these occur at a low frequency accounting for <1/3 of hereditary breast cancer and only 3% of breast cancer cases in the general population (Anglian Breast Cancer Study Group, 2000; Ford et al., 1998; Newman et al., 1998; Whittemore et al., 1997) . Therefore, the susceptibility alleles underlying the majority of heritable breast cancer remain to be identified. Intensive efforts during the past decade have sought additional highly penetrant genes (hypothetical "BRCA3" gene), however the search remains largely unfulfilled.
The inability to detect additional high-penetrance breastcancer susceptibility alleles has stimulated interest in the role of low-penetrance modifier alleles in heritable breast cancers. Though low-penetrance alleles may be very frequent in the population, breast cancer would occur in only a small fraction of individuals carrying these alleles. In this situation it would be difficult to recognize familial clustering. Therefore, low-penetrance alleles are likely to contribute to a significant fraction of what is presently recognized as sporadic breast cancer (Nathanson et al., 2001; Ponder, 2001) . Modeling the genetic basis of breast cancer indicated that more than 50% of breast cancers may originate from the 12% population that are highly susceptible to cancer This suggests that most of the genetic predisposition to breast cancer may be connected to low-penetrance risk alleles which are common among the general population.
The significanceof low-penetrance modifers is also evident in breastcancer families with known mutations.
While mutations in BRCAI and BRCA2 appear to cause strikingly similar clinical disease in twins (Delgado et al., 2002 ) the penetrance of breast cancervaries between 28% and 85% am ong different populations carrying BRCA 1 susceptibility alleles (Fodor et al., 1998; Nathanson et al., 2001 ; Warner et al., 1999) . Patients carrying germline mutations in TP53 suffer from Li-Fraumeni syndrome and are at high risk of developing multiple tum or types with early-onset breast cancer being the most common cancer in female Li-Fraumeni patients. Penetrance of breast cancer also varies considerably among women with identical mutations in TP53 (Varley et al., 1997b; Varley et al., 1997a ) which may be caused by low-penetrance alleles that modify cancer phenotypes (Ponder, 2001 ). Indeed, a single nucleotide polymorphism (SNP) in the promoter of MDM2, an inhibitorof p53 function, decreased the ageat-onset by 10 years of hereditary breast cancer in Li-Fraumeni Syndrome patients (Bond et al., 2004) Though evidence suggests a strong role for low-penetrance modifiers of breast cancer risk, genetic -3-mapping in human populations has limited power. In contrast, inbred mouse strains bearing knockout alleles of tumor suppressor genes or oncogenic transgenes can be used to examine variations in tumor phenotypes among strains and to identify genetic loci that modifycancer risk. Mice bearing a mutation in the Apc gene (Min) have been used to discover a "m odifier of Min" (Mom I or Pla2g2a) which affects turn or multiplicity and size of intestinal tumors (Cormier et al., 1997; Dietrich et al., 1993) . Expression of the polyoma middle T-antigen oncogene have been used to identify pathways that collaborate with tyrosine kinase signaling and alter the latency of mammary tumors (Le Voyer et al., 2000; Le Voyer et al., 2001; Lifsted et al., 1998; Rose-Hellekant et al., 2002) .
As mutation and loss of the p53 tumor suppressor gene is a common feature of breast cancer, we have used Trp53+/-mice as a model in which to screen for genes that modify breast cancer risk. The frequency of mammary tumors is highly strain dependent in Trp53+I-mice (Backlund et al., 2001; Kuperwasser et al., 2000b) .
The incidence of spontaneous m am marytumors is -55% among BALB/c-Trp53+/-females (Blackburn et al., 2003; Kuperwasseret al., 2000a) . In contrast, spontaneous mam mary tumors were rare (<1% incidence) among Trp53+/-mice on C57BL16-and 129/Sv backgrounds mice (Donehower et al., 1992; Harvey et al., 1993) . The incidence of mam mary tumors among (C57BL/6 x BALB/c)F1 -Trp53+/-females was intermediate compared to the the parental strains, indicating both dominant and recessive components contributing to mammary tumor susceptibility in BALB/c mice (Blackburn et al., 2003) . In this study, progeny from a backcross of (C57BL/6 x BALB/c)F1 to BALB/cTrp53-1-mice (N2-Trp53+I-) were analyzed to genetically map a recessive locus on the distal portion of chromosome 7 that contributed to the increased incidence of mammary tumors in BALBIc-Trp53+/-mice. Gene expression profiling identified DMBTI as a candidate genetic modifier. Decreased expression in mammarytissue is associated with increased susceptibility to breast cancer in humans and mice.
RESULTS

Genome scanning for mammary tumor modifiers
A total of 224 female N2-backcross mice were monitored for tumors as described in the Experimental Procedures. After histological confirmation of the mam mary tumors, mice were divided into two phenotypic groups -mice with maam mary tumors (n=85)and mice without mammary tumors (N=1 02).Agenome scan was performed on the two pools of DNA to identify mammary tumor modifier loci. The results indicated a single genomic region on chromosome 7 that had a significant association with the occurrence of mammary tumors in Trp53+/-mice ( Figure 1A ). Subsequent analysis performed using additional SNP markers indicated an interval between 101.4 -4-Mb (-IogP=2.92, marker M-09671_1) and 113.9 Mb (-log P=2.79, marker X67140_BS2) with a peak LOD score of 3.5 at 113.0 Mb (marker M64879_201_1). This chromosome 7 locus was designated SuprMaml for suppressor of mammary tum ors. Of note, there were potentially two peaks within this linkage region. This raises the possibility thatthere may be more than one gene within the interval that influences mammarytumor susceptibility. This region had a very significant effect on incidence of mammary tumors in progeny. More than half of the N2 mice (60/101) mice homozygous for the BALB/c SuprMaml allele developed mammary tumors, compared to only 25/74 in the heterozygous mice (p<0.0001, X 2 test).
The specificity and magnitude ofthe genetic effect of SuprMam I was analyzed using Kaplan-Meier survival estimates. The genotypes at marker M64879_201_1 were used for this analysis. Homozygosity for the BALB/c alleles significantly decreased mammary tumor-free survival (p=0.002). The median age of mammary tumor occurrence decreased from 70.7 weeks in heterozygotes to 61.1 weeks in homozygotes ( Figure 2 ) with homozygotes having a 2-fold increase in risk of developing a mam mary tumor compared to heterozygotes (hazard ratio of 1.93, 95% confidence interval 1.26-2.95, p=0.00 2 ). This result is consistent with expectations for lowpenetrance alleles. This effect was specific for mam mary tumor development, asanalysis of tumor-free survival for all tumor types or for any of the other major tumor types (lymphoma, osteosarcoma, adrenal gland tumor) did not show any significant decrease in survival in N2 backcross mice (hazard ratio 1.14, 95% confidence interval 0.87-1.51, p=0.3 for all tumor types). These results identify a genetic susceptibility locus with a pattern of inheritance on the distal portion of mouse chromosome 7 that specifically modifies risk of developing mammary tumors in mice.
Dmbtl as a candidate genetic modifier of breast cancer risk
Significant linkage spans the interval between 90-125 Mb of mouse chromosome 7 (SuprMaml) which encodes over 200 expressed or predicted genes. However, none of the genes within this region were known mam mary tumor susceptibility factors, nor were there any obvious candidate genes based upon known functions.
To identify candidate genetic modifiers within this interval, gene expression in mammary glands obtained from C57BL/6-and BALB/c-Trp53+/-mice were profiled using oligonucleotide microarrays. Within the SuprMam I locus 10 genes were found to be significantly different in expression between the two strains (fold change >1.6; p<0.05), including 7 ESTs and 3 genes: Teadl (TEA domain family member 1 ), Dmbtl (Deleted in malignant brain tumors 1) and Nucb2 (nucleobindin 2). Of these known genes, only Dmbtl had more than 2-fold difference in expression -5-with lower levels in the susceptible BALB/c strain, consistent with the expectations for a recess ive-acting mod ifier.
As Dmbtl has been described as a putative tumor suppressor gene (Mollenhauer et al., 2000) , itwas selected as a candidate gene for further analysis.
The difference in expression between the strains was confirmed by Northern blot hybridization. A single transcript in of -6 kb was detected in both strains which was consistent with published reports and reference sequences in UniGene. Expression in mammary glands from C57BLI6-Trp53+/-mice was over 5-fold higher than the levels in BALB/c-Trp53+I-(p=0.009, Figure 3A and 3B). This effectwas tissue-specific because levels of Dmbtl mRNA were equivalent in small intestines of C57BL/6 and BALB/c mice ( Figure 3A and B) . Alternative usage of the 3' exons of Dmbtl in mouse can result in transcripts that contain the transmembrane spanning domain (Dmbtlp3) or lack this region (Dmbtla). As small differences in the transcript size would be undetectable by
Northern blot, specific primers were designed to define the structure of the 3' ends of the transcripts using RT-PCR.
A primer pair spanning the CUB and ZP domains amplified a region common to both a and 3 forms. The results show detectable levels of Dmbtl mRNA in both strains and confirms the reduced expression in BALB/c mammary tissue ( Figure 3C ). Amplification of Dmbtl mRNA using primers specific forthe transmembrane region and 3' UTR also yielded a single band at the expected size (418 bp). No differences in amplification products were detected in small intestine. These data demonstrate that Dmbtl3 is the major transcript expressed in both strains and that levels of expression are the only difference between the strains.
Low DMBT1 expression is associated with human breast cancer
We next determined if expression of DMBTI was altered in human breast cancers. Expression of DMBTI mRNA was analyzed in normal human tissues as well as breast cancers using quantitative RT-PCR (Q-PCR). As normal breasttissue is composed of heterogeneous cell types with epithelial cells being a minority (<30% of tissue), direct comparisons with breast tumors which are enriched for epithelium can be misleading. Therefore, immortalized breast epithelial cells derived from reduction mammoplasty were used. DMBTI mRNA was low to undetectable in several normal tissues. Significant levels of DMBTI mRNA were detected only in the lung and immortalized breast epithelial cell lines (76N cell lines provided byVimla Band, Figure 4 ). In contrast, expression of DMBTI was below the limit of detection in 6 primary human breast cancers tested (Figure 4) . The decreased expression of DMBT1 mRNA in breast cancers is consistent with the proposed tumor suppressor function in breast tissue.
-6-As decreased expression of Dmbtl was associated with increased mam mary tumor susceptibility in mice, we hypothesized that lower levels of expression of DMBT1 in normal human breast epithelium may be associated with increased risk, and therefore, may be more common among women with breast cancer. To address this, variations in the staining patterns of normal, benign breast tissue for DMBT1 protein were examined by immunohistologyin a sample of 99 women, 46 with breast cancer and 53 with no historyof breast canceror other breast disease. Examples of weak, moderate and strong staining (staining intensity score 1,2 and 3 respectively) are shown in Figure 5 . Intracytoplasmic granular staining in the epithelium was the most common pattern, but varied among women. DMBT1 staining was often focal and variable, with some ducts staining strongly while adjacent ducts were negative ( Figure 5C ). Positive staining was observed in benign epithelium adjacent to tumors as well as in benign epithelium that was distant from the cancer. No consistent staining pattern in terms of the locationof benign epithelium in relationship to cancerwas noted in specimens from patientswith historyof cancer.
The DMBT1 staining within the benign glandular epithelium was semi-quantified using percentof staining as well as staining intensity to generate a staining score. Overall, women without breast cancer were more likely to show significant positive staining with scores Ž>4 (Table 1 ; 72% of controls versus 26% of breast cancer patients, p=0.008, Fisher's Exact test) and showed a greater degree of staining (Table 1 ; staining summary score median=3.9 versus median=1.8, p<0.0001, Wilcoxon Rank Sum Test). There was no significant association of age with staining score in either the cancer or no cancer group (p=0.19 and 0.75 respectively). Furthermore, adjusted analyses performed to control for age (restricted to the women aged 40-55 years) resulted in very similar findings (p=0.002, Table 1 ). Thus, DMBT 1 staining score in normal breast epithelium was loweramong patients with breast cancer compared to the cancer-free controls.
DISCUSSION
Though nearly 30% of breast cancer risk can be attributable to heritable factors (Lichtenstein et al., 2000) , the known breast cancer genes account for fewer than 5% of the breast cancer cases (Anglian Breast Cancer Study Group, 2000; Newman et al., 1998; Whittemore et al., 1997) leaving a large fraction of heritable breast cancer forwhich the genes remain to be identified. A polygenic model with low-penetrance risk alleles provides the best fit to explain the residual familial risk of breast cancer Pharoah et al., 2002) . Therefore, identification of low-penetrance risk alleles are likely to significantly improve the precision of risk assessment, but linkage studies in human pedigrees have limited power to detect these alleles.
-7-
Here we describe the use of the Trp53+/-mouse models of breast cancer to identify DMBTI as a lowpenetrance modifier of susceptibility to m am m arytum ors in mice and humans. DMBT1 was originally characterized as a gene deleted in malignant brain tumors (Mollenhauer et al., 1997) and is down-regulated in breast cancer (Braidotti et al., 2004; Mollenhauer et al., 2004) as well as other cancers of epithelial origins, including brain, skin, lung and digestive tract (Mollenhauer et al., 1997; Mollenhauer et al., 2002; Mori et al., 1999; Wu et al., 1999) .
These studies indicate a potential role for DMBT1 as a tumor suppressor, however DMBTI has not previously been considered as a breast cancer susceptibility gene. In the present study, DMBTI was identified as a candidate because it is located within the SuprMaml, a mammary tumor susceptibility locus on mouse chromosome 7.
Homozygosityforthe BALB/c allele at SuprMamI resulted in a 10 week reduction in latency and a 2-fold increase Variable expression of DMBT1 protein in normal human breast epithelium was also observed. A significant association was found between low expression of DMBT1 in normal human breast tissue and the occurrence of breast cancer among patients that were unselected for family history (Table 1 ). In this study we sought to evaluate the basal levels of DMBT1 expression in cancer patients. In contrast, Mollenhauer and co-workers included hyperplastic epithelium flanking cancers in an effort to address the hypothesis that DMBT1 expression is induced by pathophysiological processes such as inflammation and cancer . The high frequency of positive staining (17/20) At least 8 common alleles of DMBT1 have been described in humans, based on Southern blotting and sequencing of exons (Mollenhauer etal., 2000; Wu et al., 1999) . These polymorphisms may actas low-penetrance modifiers of cancer susceptibility. Some of these are thought to involve deletion of scavenger receptor cysteine rich (SRCR) domains. The highly repetitive structure of the SRCR domains raises the possibility that multiple alleles have arisen due to unequal crossing during meiosis. As none of the alleles are predicted to eliminate protein expression, they would be expected to be hypomorphic with respect to their functions. Alternatively, differences in promoter elements that alter basal expression may exist in linkage with the variants in coding regions. This may contribute to the variation in expression levels observed among individuals.
The mechanism by which DMBT1 acts as a tumor suppressor is not understood, but may be mediated through its role in epithelial cell differentiation. Secreted hensin, the DMBT1 homolog in rat, polymerizes in the extracellular matrix through galectin-3 and directs terminal differentiation of rat kidney cells (Hikita et al., 2000; Takito et al., 1999) In the mouse, hensin null embryos die at embryonic day 5.5 due to the requirement for hensin in terminal differentiation of columnar epithelia during early embryogenesis (Takito and Al Awqati, 2004) . DMBT1
is induced rapidly in response to certain pathological stresses which may mediate an unidentified protective role within epithelial cells. These stresses include tissue injury from paracetamol toxicity and hepatitis B infection in the liver (Bisgaard et al., 2002) , carcinogen exposure in the lung (Mollenhauer et al., 2002) or mammary gland . Therefore, the presence of hypomorphic alleles resulting in disrupted differentiation or stress responses are likely to contribute to tumorigenesis.
We have used the Trp53+/-mouse model of breast cancer and transcriptional profiling to identify a novel mammary tumor susceptibility locus and candidate low-penetrance modifier gene. Association of lower DMBT1 expression in normal mammary epithelium with increased likelihood of breast cancer in both mice and humans indicates the discovery of a relevant modifier of breast cancer risk. Given that genetic variants of DMBT1 are common, this gene has the potential to contribute significantly to breast cancer risk in the general population.
However, the diversity of alleles of DMBT1 raises the possibility that multiple variants may act as modifiers.
Therefore, identifying the function of DMBT1 that is relevant to cancer suppression may be necessary to ascertain which alleles confer susceptibility. With its role in terminal differentiation of epithelial cells, DM BT1 presents us with a new pathway, that of cell fate and differentiation, that can influence breast cancer risk and may be a target for -9-preventive strategies.
EXPERIMENTAL PROCEDURES
Mice and Breeding Strategy: BALB/c-Trp53+/-mice were generated previously (Jerry et al., 1998) by backcrossing C57BL/6 x 129/Sv Trp53+/-mice onto the BALB/cMed strain for 11 generations. The C57BL/6 x BALB/c intercross populations have been described previously (Blackburn et al., 2003) . Trp53+/-N2 mice were monitored weekly for tumor development or morbidity and palpated for mammary tumors.
Mice were sacrificed before tumors reached 1cm in size orwhen signs of morbiditywere observed. Tumor tissues were fixed overnight in neutral-buffered formalin, processed, and stained with H&E for histological assessment.
All tumors were examined by a qualified pathologist for diagnosis. Mammary glands without tumors were wholemounted for examination of ductal tree structure. All procedures involving animals were in accordance with institutional and national guidelines for the use of animals and were approved by the Institutional Animal Care and Use Committee at the University of Massachusetts-Amherst.
Genome scanning for mammary tumor susceptibility alleles: The initial genome scan was performed on two pools of DNA: mammary tumor (n=85) and non-mammary tumor (n=102) bearing mice. For this analysis, only mice with definite mammary epithelial lesions (adenocarcinoma, adenosquamous carcinoma or mammary intraepithelial neoplasia (MIN)) were included in the mammary tumor pool. This excluded 9 mice with carcinosarcomas of the mammary gland and 4 mice with adenocarcinomas of ambiguous mammary or salivary gland origin. The non-mammary tumor pool was restricted by age, with mice succumbing to other tumor types younger than 30 weeks (n=12) being excluded, as this was too early for a mammary phenotype to be observed.
A further 5 mice were excluded which showed unusual ductal growth patterns in wholemounted mammary glands.
This growth pattern, a secondary tree of very fine ducts originating from the nipple between ducts of the original outgrowth, was observed in 16 other mice, all of which had developed mammary tumors in other glands.
The pooled DNA sam pies were analyzed quantitatively for single nucleotide polymorphisms (SNP) at 150 markers throughout the genome (Grupe et al., 2001) . The significance of each allele frequency difference between the two groups was calculated using the z-test and plotted as a LOD score (-IogP). In regions of significant -10-association (-IogP > 3.3), markers were genotyped in individual mice for confirmation, and finer mapping with additional markers was performed. Using the genotype at the marker with the highest LOD score, Kaplan-Meier estimates of the tumor-free survival curves were calculated and plotted for homozygotes and heterozygotes. The median time to tumor was used for comparison of latencies and the significance of differences in latency (tumorfree survival times) and were analyzed by the log-rank test.
Expression Microarray Analysis: Mammary glands from C57BL/6-and BALB/c-Trp53+/-mice were collected from 12 week old virgins and snap frozen in liquid nitrogen. Total RNA was reverse transcribed using a T7-promoter coupled oligo(d)T primer (GeneChip T7-Oligo(d)T Promoter Primer Kit, Affymetrix, Santa Clara, CA).
After the second-strand cDNA synthesis, an in vitro transcription (IVT) reaction was performed using an Enzo
BioArray High Yield RNA transcript labeling kit (Affymetrix). The labeled samples were hybridized to the Murine Genome U74v2 set that contains probe sets for approximately 36,000 full-length mouse genes and EST clusters from the UniGene database (Affymetrix). GeneChips were scanned using the GS2500 scanner and images were analyzed by Affymetrix software (Microarray Analysis Suite version 5.0). Four mice of each strain were analyzed with pairwise comparisons. Genes showing at least 2-fold expression differences and with p value < 0.05 were considered to be differentially expressed.
RT-PCR for mouse Dmbtl:
Mammary glands and small intestines from C57BL/6-and BALB/c-Trp53+/-mice were collected from 8 week-old virgin females as described above. Total RNA was extracted from these tissues using QIAzol reagent (Q IAgen, CA) following the m anufacturer's manual. 1 [ig of each tissue total RNA was reverse transcribed using AMV (Seikagaku America, MA) in a 20 [l reaction mix using protocols developed by Roche (CA). 5 p. of the cDNA products were then am plified using 2 sets of forward and reverse primers with: CUB5
(5'-AGCACAAGTCTCCATCACCCAAACA-3') and ZP3 (5'-GATTGGTGGTGTTATTGTCAAAGTC-3'); TM5 (5'-ATCTTTGGCGGAGTCTTCCTGG-3') and UTR3 (5'-GTTGGCTATACATGGGGAAAAGGG-3'). The annealing temperature for the primer pairs was 60°C and product sizes were 761 and 418 bp, respectively. Mouse actin was also amplified as a control using primers Actin5F (5'-TGCTGTCCCTGTATGCCTCT-3') and Actin3R (5'-TGCCACAGGATTCCATACCC-3'), which anneal to the cDNA template at 60'C and produce a 405bp product.
Polymerase chain reaction (PCR) was performed with 300 pmol/ml of each primer in a 20 ld reaction volume containing 1 x PCR buffer (Sigma), 2 mM MgCI 2 (Sigma), 250 ltM dNTPs (Sigma) and 0.5 units ofTaq polymerase (Sigma). 30 cycles of [94°C 1 min, 60°C 1 min, 72°C 1 min] were performed. The products were run on agarose -11-gels and viewed by ethidium bromide staining.
RT-PCR for human DMBTI:
RNA from normal human tissues was purchased from Clontech (Palo Alto, CA). RNA was isolated from the 76N breast epithelial cell line series, normal cells immortalized with telomerase, mutant p53 or E6 (76N+hTERT, 76N+p53mt and 76N+E6 respectively) (Cao et al., 1997; Gao et al., 1996) Northern blot analysis: Northern blotanalysis was preformed as described previously (Jerry et al., 1998) .
10 V.g of total RNA from each tissue were subject to electrophoresis on a 1.2% agarose-formaldehyde gel, then immobilized onto nylon membranes (CUNO Laboratory Products, CT). The membranes were hybridized to cDNA probes labeled with Dmbtl were standardized for loading by comparison to bands hybridized with a probe for Gapdh, and the significance of differences was determined by t-tests.
Immunohistochemistry for DMBTI:
The immunohistochemical expression of DMBT1 was evaluated in benign breast glandular epithelium from 53 patients without a historyof carcinoma (46 reduction mainmoplasties and 7 excisional breast biopsies for ectopic (axillary) mass or calcifications found to be benign) and in benign breast glandular epithelium from 46 patients with a history of breast carcinoma (6 ductal carcinoma in-situ, 6 infiltrating lobular carcinomas, and 34 infiltrating ductal carcinomas). All cases were formalin fixed paraffin embedded were confirmed by review of the original hematoxylin and eosin stained slides. The DMBT1 protein expression was evaluated by immunohistochemistry with anti-DMBT1h12 monoclonal antibody provided by Jan Mollenhauer, (Mollenhauer et al., 2000) utilizing standard protocols on a DAKO automated platform. The primary antibody was used at a dilution of 1:250 for 60 minutes at room temperature. The antibody complex was detected using a polymer-based amplification system (Envision+, DAKO, Carpinteria, CA).
Intracytoplasmic granular staining in the epithelium was the most common pattern of staining and was regarded as positive. Imm unoreactivity in inflammatory cells and stroma was infrequent and was not considered in this study. The imm unohistochemical expression of DMBT1 within the glandular epithelium was semi-quantified using percent of staining as well as staining intensity. Staining percentage was quantified as follows: 0 = no staining; 1 = <5%; 2 = 6-50%; 3 = >50% of cells with positive staining. A separate score was given for staining intensity; 0 = no staining; 1 = weak staining; 2 = moderate staining; 3 = strong staining). The scores for staining percentage and intensitywere com bined for an overall score. The staining score was assessed by two pathologists independently (Q.J.C. and R.S.J.R.)with consensus recorded. Cases with combined scores of 0-2were considered negative. Cases with a score >4 (with 6 being the maximum) were considered significantly positive.
Comparisons of the occurrence of significant positive staining (score Ž4) and the average staining score in women with breast cancer versus cancer-free controls were made using Fisher's exact tests and Wilcoxon rank sum tests respectively. Adjusted analyses to control for age were performed in addition to analyses on the whole set of results, and the association of age with staining was examined by Fisher's exact test on subgroups of the samples. The variance of each group was compared using variance ratio tests. All analyses were performed using the STATA statistical software package. and polarized toward the luminal surface was considered "score=2". (C) Intense staining polarized toward the luminal surface was considered "score=3".
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